Gontivimab (ALX-0171; VR-465) is a poent anti-RSV prefusion F protein nanobody with a KD value of 0.113 nM. Gontivimab shows antiviral activity. Gontivimab reduces the RSV load in the nose and lung[1].
in vivo
Gontivimab (1-68 mg/kg; intranasal administration or nebulization) reduces the RSV load in the nose and lungs in rats[1].
Animal Model:
Rats (RSV Tracy)[1]
Dosage:
1-68 mg/kg
Administration:
Intranasal administration or nebulization; once (day 2 or day 3) or twice (day 2 and day 3)
Result:
Resulted in significant viral load reductions in the lungs ranging.
References
[1] Detalle L, et al. Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection. Antimicrob Agents Chemother. 2015 Oct 5;60(1):6-13. DOI:10.1128/AAC.01802-15
